Psoriasis: IL23 Inhibitors

FDA Approves Tremfya (guselkumab) for Plaque Psoriasis (VOYAGE & NAVIGATE Trials)

The U.S. Food and Drug Administration (FDA) has approved the IL-23 inhibitor, Tremfya (guselkumab), for patients with moderate to severe plaque psoriasis.
rheumnow.com

Guselkumab tops adalimumab for psychiatric comorbidities in psoriasis (VOYAGE 2)

Treatment with guselkumab was associated with…
mdedge.com

Tildrakizumab, an IL-23 Inhibitor, is Successful in Plaque Psoriasis

Therapeutic options for cutaneous psoriasis (and psoriatic arthritis as well) are rapidly expanding.  Lancet has published the impressive results of two phase III trials of tildrakizumab, a IgG1 antibody against interleukin 23 p19, in patients with active chronic plaque psoriasis.
rheumnow.com

Risankizumab Outperforms Humira, Stelara in Treating Plaque Psoriasis (IMMvent & UltlMMa Trials)

As AbbVie’s best-selling Humira faces oncoming biosimilar competition, the drug maker is developing a new innovator product that could help it retain a hold on the…
centerforbiosimilars.com

Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis

Original Article from The New England Journal of Medicine — Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis
nejm.org

No Comments Yet.

Leave a comment